AbbVie says it has positive mid-stage data for Rinvoq in lupus, will move to PhIII
AbbVie is teasing new Phase II data in the most common form of lupus — and the pharma company says it is good enough to move …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
